Loading
A phase 3 trial of Pafolacianine in Lung cancer, run by On Target Laboratories, LLC, completed.
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting is a phase 3 interventional study registered as NCT04241315 by On Target Laboratories, LLC, with 112 participants recorded, started 2020-03-26 and reaching its primary completion in 2021-10-07. Interventions recorded: OTL38 for Injection, Near infrared camera imaging system. Conditions recorded: Lung Neoplasms, Lung Cancer.
Linked to the drug Pafolacianine because the registry names it among its interventions and Lung cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Pafolacianine and the tag pipeline.
Shares Pafolacianine and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.
Shares Lung cancer (all types) and the tag pipeline.